Dr. Boyle is an Associate Professor in the Department of Medicine in the David Geffen School of Medicine. Dr. Boyle leads an important consultation service for CTSI DGSOM faculty related to the discoveries-to-products pipeline. He also has a leading role in the DGSOM Accelerator to identify emerging technologies and drug concepts to help drive the value generation of university assets that will bring in revenues to help fund internal programs and other initiatives. As a senior executive with over 20 years of experience in the pharmaceutical and biotechnology industry, he is highly qualified for this role. Dr. Boyle has extensive experience in translational medicine, project management, target selection, pipeline management, and platform translation. Dr. Boyle received his doctorate degree in Experimental Pathology from the UCLA School of Medicine and subsequently completed a postdoctoral fellowship in Molecular Biology and Virology at the Salk Institute. He began his research career at Amgen in 1990, where he was involved in the discovery and development of novel protein and small molecule candidate therapeutics for over eleven years. His research in discovery and development within the immunology/inflammation, oncology, and bone therapeutic areas has been published extensively in peer-reviewed journals.
Bowers Peter M, Horlick Robert A, Neben Tamlyn Y, Toobian Rachelle M, Tomlinson Geoffrey L, Dalton Jennifer L, Jones Heather A, Chen Andy, Altobell Laurence, Zhang Xue, Macomber John L, Krapf Irina P, Wu Betty F, McConnell Audrey, Chau Betty, Holland Trevin, Berkebile Ashley D, Neben Steven S, Boyle William J, King David J,
Coupling mammalian cell surface display with somatic hypermutation for
the discovery and maturation of human antibodies
Proceedings of the National Academy of Sciences of the United States of America.
Kostenuik Paul J, Nguyen Hung Q, McCabe James, Warmington Kelly S, Kurahara Carol, Sun Ning, Chen Ching, Li Luke, Cattley Russ C, Van Gwyneth, Scully Shelia, Elliott Robin, Grisanti Mario, Morony Sean, Tan Hong Lin, Asuncion Frank, Li Xiaodong, Ominsky Michael S, Stolina Marina, Dwyer Denise, Dougall William C, Hawkins Nessa, Boyle William J, Simonet William S, Sullivan John K,
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone
resorption and increases BMD in knock-in mice that express chimeric
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
Shalhoub V, Elliott G, Chiu L, Manoukian R, Kelley M, Hawkins N, Davy E, Shimamoto G, Beck J, Kaufman S A, Van G, Scully S, Qi M, Grisanti M, Dunstan C, Boyle W J, Lacey D L,
Characterization of osteoclast precursors in human blood
British journal of haematology.
Lacey D L, Tan H L, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess T L, Boyle W J, Polverino A J,
Osteoprotegerin ligand modulates murine osteoclast survival in vitro
and in vivo
The American journal of pathology.
Min H, Morony S, Sarosi I, Dunstan C R, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik P J, Lacey D L, Boyle W J, Simonet W S,
Osteoprotegerin reverses osteoporosis by inhibiting endosteal
osteoclasts and prevents vascular calcification by blocking a process
The Journal of experimental medicine.